Status:
COMPLETED
AT1R Blockade and Periodic Breathing During Sleep in Hypoxia
Lead Sponsor:
University of British Columbia
Conditions:
Sleep Disordered Breathing
Hypoxia
Eligibility:
All Genders
18-45 years
Phase:
PHASE4
Brief Summary
Sleep disordered breathing (SDB) is characterized by regular periods of no breathing (apnea) or low levels of breathing (hypopnea) and leads to repeated periods of low oxygenation, termed intermittent...
Detailed Description
Objective: To determine the effects of angiotensin-II, type-I receptor (AT1R) blockade on the relationship between ventilatory control and sleep disordered breathing (SDB) following a night of hypoxic...
Eligibility Criteria
Inclusion
- normotensive
- forced expiratory volume in 1s : forced vital capacity ratio \> 0.75
- no medical history of cardiovascular and respiratory disease
- not taking medications other than oral contraceptives
- free from sleep apnea
- body mass index less than 30 kg/m2
Exclusion
- history of hypertension
- known impaired renal function
- liver disease
- heart failure
- myocardial infarction
- coronary artery disease
- smoked within the past year
- apnea hypopnea index \> 5 events per hour
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2019
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03335904
Start Date
January 1 2018
End Date
August 1 2019
Last Update
September 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of British Columbia
Kelowna, British Columbia, Canada, V1V 1V7